| 1. |
汪曉東, 呂炘沂, 黃明君, 等. 數據庫建設第二部分: 結直腸癌住院流程管理的標簽與結構化. 中國普外基礎與臨床雜志, 2019, 26(7): 852-855.
|
| 2. |
汪曉東, 李立. 數據庫建設第一部分: 個人數據的標簽與結構化. 中國普外基礎與臨床雜志, 2019, 26(3): 335-342.
|
| 3. |
汪曉東, 劉健博, 安麗珉, 等. 數據庫建設第四部分: 結直腸癌的術前專科檢查與評估的標簽與結構化, 2019, 26(11): 1337-1341.
|
| 4. |
Dijkstra EA, Hospers GAP, Kranenbarg EM, et al. Quality of life and late toxicity after short-course radiotherapy followed by chemotherapy or chemoradiotherapy for locally advanced rectal cancer—The RAPIDO trial. Radiother Oncol, 2022, 171: 69-76.
|
| 5. |
Yang J, Wang W, Luo Y, et al. Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis. Tech Coloproctol, 2022, 26(3): 163-174.
|
| 6. |
Lin W, Li C, Clement EA, et al. Surgical outcomes in total neoadjuvant therapy for rectal cancer versus standard long-course chemoradiation: a systematic review and meta-analysis of randomized controlled trials. Ann Surg, 2024, 279(4): 620-630.
|
| 7. |
Gollins S, Sebag-Montefiore D. Neoadjuvant treatment strategies for locally advanced rectal cancer. Clin Oncol (R Coll Radiol), 2016, 28(2): 146-151.
|
| 8. |
國家衛生健康委員會醫政司, 中華醫學會腫瘤學分會. 中國結直腸癌診療規范(2023版). 協和醫學雜志, 2023, 14(4): 706-733.
|
| 9. |
Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.
|
| 10. |
Gerard JP, Barbet N, Schiappa R, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact X-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol, 2023, 8(4): 356-367.
|
| 11. |
Tan S, Ou Y, Huang S, et al. Surgical, oncological, and functional outcomes of local and radical resection after neoadjuvant chemotherapy or chemoradiotherapy for early- and mid-stage rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis, 2023, 38(1): 132. doi: 10.1007/s00384-023-04433-6.
|
| 12. |
汪曉東, 劉健博, 安麗珉, 等. 數據庫研究第四部分: 結直腸癌的術前專科檢查與評估. 中國普外基礎與臨床雜志, 2019, 26(10): 1230-1238.
|
| 13. |
汪曉東, 由屹先, 余其澳, 等. 數據庫建設第九部分: 結直腸癌新輔助治療的標簽與結構化. 中國普外基礎與臨床雜志, 2021, 28(6): 799-804.
|
| 14. |
陳功勤, 張洋, 郭慧, 等. 不同新輔助治療方案對直腸癌患者TRG、手術并發癥及LARS的影響. 腫瘤防治研究, 2021, 48(12): 1108-1112.
|
| 15. |
李立, 汪曉東. 以價值醫療為導向的結直腸癌標準數據集. 四川科學技術出版社, 2023.
|
| 16. |
Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021, 22(1): 29-42.
|
| 17. |
P?hlman L. Neoadjuvant and adjuvant radio- and radio-chemotherapy of rectal carcinomas. Int J Colorectal Dis, 2000, 15(1): 1-8.
|
| 18. |
汪泓, 羅文廣, 張紅雁, 等. 直腸癌新輔助放化療后病理完全緩解的臨床預測因素分析. 安徽醫學, 2024, 45(9): 1100-1105.
|
| 19. |
劉健博, 呂炘沂, 鄒雨恒, 等. 多周期新輔助化療聯合阿帕替尼對進展期直腸癌的療效評價: 基于DACCA數據庫的輔助研究. 中國普外基礎與臨床雜志, 2019, 26(6): 728-734.
|
| 20. |
汪曉東, 邱萌, 李亞倫, 等. 多學科協作診治模式下結直腸癌不同周期新輔助化療聯合手術的方案研究. 中國普外基礎與臨床雜志, 2008, 15(3): 210-214, 217.
|
| 21. |
Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: Initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase Ⅲ trial. J Clin Oncol, 2016, 34(27): 3300-3307.
|
| 22. |
郭旭飛. 術前短程放療聯合新輔助化療治療中低位局部進展期直腸癌效果及安全性分析. 中國醫學物理學雜志, 2024, 41(12): 1481-1485.
|
| 23. |
胡欲飛. 新輔助化療Folfoxiri方案在中低位進展期直腸癌治療的安全性和有效性分析. 十堰: 湖北醫藥學院, 2024.
|
| 24. |
Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol, 2018, 4(6): e180071. doi: 10.1001/jamaoncol.2018.0071.
|
| 25. |
Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol, 2022, 40(23): 2546-2556.
|
| 26. |
萬覺鋒, 章真. 直腸癌術前放療進展. 中華結直腸疾病電子雜志, 2016, 5(2): 127-132.
|
| 27. |
Helbling D, Bodoky G, Gautschi O, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase Ⅱ trial SAKK 41/07. Ann Oncol, 2013, 24(3): 718-725.
|
| 28. |
Pinto C, Di Fabio F, Maiello E, et al. Phase Ⅱ study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol, 2011, 22(11): 2424-2430.
|
| 29. |
Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 2009, 73(2): 466-472.
|
| 30. |
Kripp M, Horisberger K, Mai S, et al. Does the addition of cetuximab to radiochemotherapy improve outcome of patients with locally advanced rectal cancer? Long-term results from phase Ⅱ trials. Gastroenterol Res Pract, 2015, 2015: 273489. doi: 10.1155/2015/273489.
|
| 31. |
劉勇, 汪曉東, 由屹先, 等. 數據庫研究第九部分: 結直腸癌的新輔助治療. 中國普外基礎與臨床雜志, 2021, 28(5): 657-663.
|
| 32. |
中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)結直腸癌診療指南. 北京: 人民衛生出版社, 2023.
|
| 33. |
Mbanu P, Saunders MP, Mistry H, et al. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy. Phys Imaging Radiat Oncol, 2022, 23: 48-53.Mbanu P, Saunders MP, Mistry H, et al. Clinical and radiomics prediction of complete response in rectal cancer pre-chemoradiotherapy. Phys Imaging Radiat Oncol, 2022, 23: 48-53.
|
| 34. |
Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015, 115(2): 246-252.Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol, 2015, 115(2): 246-252.
|
| 35. |
盧琳, 趙清葉, 宋婷婷, 等. 老年局部進展期中低位直腸癌新輔助放化療效果的影響因素. 中國老年學雜志, 2019, 39(19): 4726-4728.
|
| 36. |
Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol, 2011, 29(35): 4633-4640.
|
| 37. |
楊慶, 張濤. 直腸癌新輔助治療后臨床完全緩解的評估. 現代腫瘤醫學, 2016, 24(17): 2815-2819.
|
| 38. |
Kong JC, Guerra GR, Warrier SK, et al. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis, 2018, 20(7): 574-585.
|
| 39. |
Lu X, Qi R, Xu Y, et al. Tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: influencing factors and prognostic significance. Int J Clin Exp Pathol, 2023, 16(6): 124-132.
|
| 40. |
何蕾. 直腸癌新輔助放化療后淋巴結與腫瘤消退分級相關性研究. 電子科技大學, 2023.
|
| 41. |
Boldrini L, Charles-Davies D, Romano A, et al. Response prediction for neoadjuvant treatment in locally advanced rectal cancer patients-improvement in decision-making: A systematic review. Eur J Surg Oncol, 2024 Nov 15: 109463. doi: 10.1016/j.ejso.2024.109463.
|
| 42. |
胡義銧, 劉碧瑤, 張雯迪, 等. 基于CT影像組學的局部進展期直腸癌新輔助放化療效果的預測模型研究. 中國普外基礎與臨床雜志, 2025, 32(2): 205-212.
|
| 43. |
Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol, 2008, 15(12): 3471-3477.Beddy D, Hyland JM, Winter DC, et al. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol, 2008, 15(12): 3471-3477.
|
| 44. |
薛立杰. 局部進展期直腸癌新輔助放化療后腫瘤消退分級的影響因素及預后分析. 福州: 福建醫科大學, 2017.
|
| 45. |
Xu L, Cai S, Xiao T, et al. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study. Colorectal Dis, 2017, 19(7): O263-O271. doi: 10.1111/codi.13757.
|
| 46. |
Park YJ, Oh BR, Lim SW, et al. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol, 2010, 26(4): 279-286.Park YJ, Oh BR, Lim SW, et al. Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy. J Korean Soc Coloproctol, 2010, 26(4): 279-286.
|
| 47. |
Bozzetti F, Andreola S, Bertario L. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1998, 13(1): 54-55.Bozzetti F, Andreola S, Bertario L. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 1998, 13(1): 54-55.
|
| 48. |
吳桂儀, 賀子妍, 唐盈, 等. 結直腸癌患者居住地與新輔助依從性、方案決策和療效的關系: 基于DACCA的真實世界數據研究. 中國普外基礎與臨床雜志, 2023, 30(8): 911-918.
|
| 49. |
唐盈, 蘇語, 聶皓苒, 等. 結直腸癌患者的文化程度與新輔助方案決策和療效的關系: 基于DACCA的真實世界數據研究. 中國普外基礎與臨床雜志, 2023, 30(10): 1200-1204.
|